The role of peptides in blood-brain barrier nanotechnology

Journal of Peptide Science

Volumn 14, Issue 2, 2008, Pages 163-173

  Teixidó, Meritxell ^a   Giralt, Ernest ^a,b  

^a INSTITUTE FOR RESEARCH IN BIOMEDICINE   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Blood brain barrier; Nanoparticle; Nanoplatform; Nanotechnology; Peptides

Indexed keywords

ALBUMIN; ANESTHETIC AGENT; ANTICONVULSIVE AGENT; ANTINEOPLASTIC AGENT; BENZYLOXYCARBONYLASPARTYLGLUTAMYLVALYLASPARTYL FLUOROMETHYL KETONE; CONTRAST MEDIUM; DEXTRAN; DOXORUBICIN; FERUMOXTRAN 10; GADOLINIUM; GLYCOPROTEIN P; KYOTORPHIN; LEUCINE ENKEPHALIN[2 DEXTRO ALANINE 6 ARGININE]; LIPOSOME; MANNITOL; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY OX26; MRZ 2 276; NANOPARTICLE; NC 1900; PACLITAXEL; PEPTIDE DERIVATIVE; POLYMER; PRODRUG; PROTEIN DERIVATIVE; SOLID LIPID NANOPARTICLE; THIOFLAVINE; TUBOCURARINE CHLORIDE; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASOPRESSIN DERIVATIVE;

ALZHEIMER DISEASE; BLOOD BRAIN BARRIER; BRAIN BIOPSY; BRAIN BLOOD FLOW; BRAIN CANCER; BRAIN DISEASE; BRAIN INFECTION; BRAIN ISCHEMIA; BRAIN SURGERY; BRAIN TUMOR; CARDIOTOXICITY; DRUG BLOOD LEVEL; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG SAFETY; DRUG TARGETING; DRUG TRANSPORT; HISTOPATHOLOGY; HUMAN; HYPERTENSION; MEMBRANE PERMEABILITY; NANOTECHNOLOGY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN FUNCTION; REVIEW;

ANIMALS; BLOOD-BRAIN BARRIER; BRAIN DISEASES; DRUG CARRIERS; HUMANS; MAGNETIC RESONANCE IMAGING; NANOTECHNOLOGY; PEPTIDES;

EID: 39649113095     PISSN: 10752617     EISSN: 10991387     Source Type: Journal    
DOI: 10.1002/psc.983     Document Type: Review

References (126)

1. Mullin JM, Agostino N, Rendon-Huerta E, Thornton JJ. Epithelial and endothelial barriers in human diseases. Drug Discov. Today 2005; 10: 395-408.
2. Calabria AR, Shusta EV. Blood-brain barrier genomics and proteomics: elucidating phenotype, identifying disease targets and enabling drug delivery. Drug Discov. Today 2006; 11: 792-799.
3. Jain KK. The role of nanobiotechnology in drug discovery. Drug Discov. Today 2005; 10: 1435-1442.
4. Pardridge WM. Brain Drug Targeting: The Future of Brain Drug Development. Cambridge University Press: Cambridge, 2001.
5. Pardridge WM. Introduction to the Blood-Brain Barrier: Methodology, Biology and Pathology. Cambridge University Press: Cambridge, 1998.
6. Garcia-Garcia E, Andrieux K, Gil S, Couvreur P. Colloidal carriers and blood-brain barrier (BBB) translocation: A way to deliver drugs to the brain? Int. J. Pharm. 2005; 298: 274-292.
7. Mackinc J, Stins M, McComb JG, Calero M, Ghiso J, Kim KS, Yan SD, Stern D, Schmidt AM, Fragione B, Zlokovic BV. Human blood-brain barrier receptors for Alzheimer's amyloid-b 1-40. J. Clin. Invest. 1998; 102: 734-743.
8. Neuwelt EA, Mechanisms of diseases: the blood-brain barrier. Neurosurgery 2004; 54: 131-142.
9. Wolka AM, Huber JD, Davis TP. Pain and the blood-brain barrier: obstacles to drug delivery. Adv. Drug Deliv. Rev. 2003; 55: 987-1006.
10. Schlageter KE, Molnar P, Lapin GD, Groothuis DR. Microvessel organization and structure in experimental brain tumors: Microvessel populations with distinctive structural and functional properties. Microvasc. Res. 1999; 58: 312-328.
11. Vajkoczy P, Menger MD. Vascular microenvironment in gliomas. Cancer Treat. Res. 2004; 117: 249-262.
12. Kakinuma K, tanaka R, Takahashi H, Watanabe M, Nakagawa T, Kuroki M. Targeted chemotherapy for malignant brain tumor using thermosensitive liposome and localized hyperthermia. J. Neurosurg. 1996; 84: 180-184.
13. Illum L. Transport of drugs from the nasal cavity to the central nervous system. Eur. J. Pharm. Sci. 2000; 11: 1-18.
14. Graff CL, Pollack GM. Nasal drug administration: Potential for targeted central nervous system delivery. J. Pharm. Sci. 2005; 94: 1187-1195.
15. Vyas TK, Babbar AK, Sharma RK, Singh S, Misra A. Preliminary brain-targeting studies on intranasal mucoadhesive microemulsions of sumatriptan. AAPS PharmSciTech 2006; 7: E8.
16. Kao HD, Traboulsi A, Itoh S, Dittert L, Hussain A. Enhancement of the systemic and CNS specific delivery of L-dopa by the nasal administration of its water soluble prodrugs. Pharm. Res. 2000; 17: 978-984.
17. Abbott JN, Romero IA. Transporting therapeutics across the blood-brain barrier. Mol. Med. Today 1996; 2: 106-113.
18. Bodor N, Buchwald P. Barriers to remember: brain-targeting chemical delivery systems and Alzheimer's disease. Drug Discov. Today 2002; 7: 766-774.
19. Song BW, Vinters HV, Wu D, Pardridge WM. Enhanced neuroprotective effects of basic fibroblast growth factor in regional brain ischemia after conjugation to a blood-brain barrier delivery vector. J. Pharmacol. Exp. Ther. 2002; 301: 605-610.
20. Kreuter J. Nanoparticles and nanocapsules-new dosage forms in the nanometer size range. Pharm. Acta Helv. 1978; 53: 33-39.
21. Poole CP, Owens FJ. Introduction to Nanotechnology. Wiley: Hoboken, 2003.
22. Bodmeier R, Maincent P. In Pharmaceutical Dosage forms: Disperse Systems. Vol. 3, Lieberman HA, Rieger MM, Banker GS (eds). Marcel Dekker: New York, 1998; 87-127.
23. Couvreur P, Dubernet C, Puisieux F. Controlled drug delivery with nanoparticles. Current possibilities and future trends. Eur. J. Pharm. Biopharm. 1995; 41: 2-13.
24. Gref R, Minamitake Y, Peracchia MT, Trubetskoy V, Torchilin V, Langer R. Biodegradable long-circulating polymer nanospheres. Science 1994; 263: 1600-1603.
25. Perez C, Sanchez A, Putnam D, Ting D, Langer R, Alonso MJ. Poly(lactic acid)-poly(ethylene glycol) nanoparticles as new carriers for the delivery of plasmid DNA. J. Control. Rel. 2001; 75: 211-224.
26. Albrecht MA, Evans CW, Raston CL. Green chemistry and the health implications of nanoparticles. Green Chem. 2006; 8: 417-432.
27. Borm PJ, Kreyling W. Toxicological hazards of inhaled nanoparticles-potential implications for drug delivery. J. Nanosci. Nanotechnol. 2004; 4: 521-531.
28. Mykhaylyk O, Cherchenko A, Ilkin A, Dudchenko N, Ruditsa V, Novoseletz M, Zozulya Y. Glial brain tumor targeting of magnetite nanoparticles in rats. J. Magn. Magn. Mater. 2001; 225: 241-247.
29. Lovin JD, Wesbey GE, Engelstad BL, Sosnovsky G, Moseley M, Tuck DL, Brasch RC. Magnetic field dependence of spin-lattice relaxation enhancement using piperidinyl nitroxyl spin-labels. Magn. Reson. Imaging 1985; 3: 73-81.
30. Wesbey GE, Brasch RC, Goldberg HI, Engelstad BL, Moss AA. Dilute oral iron solutions as gastrointestinal contrast agents for magnetic resonance imaging; initial clinical experience. Magn Reson. Imaging 1985; 3: 57-64.
31. Dupas B, Berreur M, Rohanizadeh R, Bonnemain B, Meflah K, Pradal G. Electron microscopy study of intrahepatic ultrasmall superparamagnetic iron oxide kinetics in the rat. Relation with magnetic resonance imaging. Biol. Cell 1999; 91: 195-208.
32. Murillo TP, Sandquist C, Jacobs PM, Nesbit G, Manninger S, Neuwelt EA. Imaging brain tumors with ferumoxtran-10, a nanoparticle magnetic resonance contrast agent. Therapy 2005; 2: 871-882.
33. Manninger SP, Muldoon LL, Nesbit G, Murillo T, Jacobs PM, Neuwelt EA. An exploratory study of ferumostran-10 nanoparticles as a blood-brain barrier imaging agent targeting phagocytic cells in CNS inflammatory lesions. Am. J. Neuroradiol. 2005; 26: 2290-2300.
34. Yang CS, Chang CH, Tsai PJ, Chen WY, Tseng FG, Lo LW. Nanoparticle-based in vivo investigation on blood-brain barrier permeability following ischemia and reperfusion. Anal. Chem. 2004; 76: 4465-4471.
35. Kircher MF, Mahmood U, King RS, Weissleder R, Josephson L. A multimodal nanoparticle for preoperative magnetic resonance imaging and intraoperative optical brain tumor delineation. Cancer Res. 2003; 63: 8122-8125.
36. Veiseh O, Sun C, Gunn J, Kohler N, Gabikian P, Lee D, Bhattarai N, Ellenbogen R, Sze R, Hallahan A, Olson J, Zhang M. Optical and MRI multifunctional nanoprobe for targeting gliomas. Nano Lett. 2005; 5: 1003-1008.
37. Remsen LG, McCormick CI, Roman-Goldstein S, Nilaver G, Weissleder R, Bogdanov A, Hellström I, Kroll RA, Neuwelt EA. MR of carcinoma-specific monoclonal antibody conjugated to monocrystalline iron oxide nanoparticles: the potential for noninvasive diagnosis. Am. J. Neuroradiol. 1996; 17: 411-418.
38. Härtig W, Paulke BR, Varga C, Seeger J, Harkany T. Electron microscopic analysis of nanoparticles delivering thioflavin-T after intrahippocampal injection in mouse: implications for targeting β-amyloid in Alzheimer's disease. Neurosci. Lett. 2003; 338: 174-176.
39. Koo YEL, Reddy GR, Bhojani M, Schneider R, Philbert MA, Rehemtulla A, Ross BD, Kopelman R. Brain cancer diagnosis and therapy with nanoplatforms. Adv. Drug Delv. Rev. 2006; 58: 1556-1577.
40. Badruddoja MA, Black KL. Improving the delivery of therapeutic agents to CNS neoplasms: a clinical review. Front. Biosci. 2006; 11: 1466-1478.
41. Kreuter J. Nanoparticulate systems for brain delivery of drugs. Adv. Drug Deliv. Rev. 2001; 47: 65-81.
42. Lockman PR, Mumper RJ, Khan MA, Allen DD. Nanoparticle technology for drug delivery across the blood-brain barrier. Drug Dev. Ind. Pharm. 2002; 28: 1-13.
43. Miller G. Drug targeting. Breaking down barriers. Science 2002; 297: 1116-1118.
44. Muller RH, Keck CM. Drug delivery to the brain-realization by novel drug carriers. J. Nanosci. Nanotechnol. 2004; 4: 471-483.
45. Tiwari SB, Amiji MM. A review of nanocarrier-based CNS delivery systems. Curr. Drug Deliv. 2006; 3: 219-232.
46. Unger EC, Porter T, Culp W, Labell R, Matsunaga T, Zutshi R. Therapeutic applications of lipid-coated microbubbles. Adv. Drug Deliv. Rev. 2004; 56: 1291-1314.
47. Bazile DV, Ropert C, Huve P, Verrecchia T, Marland M, Frydman A, Veillard M, Spenleuhauer G. Body distribution of fully biodegradable [14C]-poly(lactic acid) nanoparticles coated with albumin after parenteral administration to rats. Biomaterials 1992; 13: 1093-1102.
48. Stolnik S, Dunn SE, Garnett MC, Davies MC, Coombes AG, Taylor DC, Irving MP, Purkiss SC, Tadros TF. Surface modification of poly(lactide-co-glycolide) nanospheres by biodegradable poly(lactide)-poly(ethylene glycol)copolymers. Pharm. Res. 1994; 11: 1800-1808.
49. Gref R, Luck M, Quellec P, Marchand M, Dellacherie E, Harnisch S, Blunk T, Muller RH. 'Stealth' corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption. Colloids Surf., B: Biointerfaces 2000; 18: 301-313.
50. Sparreboom A, Van Asperen J, Mayer U, Schinkel AH, Smit JW, Meijer DKF, Borst P, Nooijen WJ, Beijnen JH, Van Tellingen O. Limited oral bioavailability and active epithelial excretion of paclitaxel (taxol) caused by P-glycoprotein in the intestine. Proc. Natl. Acad. Sci. U.S.A. 1997; 94: 2031-2035.
51. Friese A, Seiller E, Quack G, Lorenz B, Kreuter J. Increase of the duration of the anticonvulsive activity of a novel NMDA receptor antagonist using poly(butylcyanoacrylate) nanoparticles as a parenteral controlled release system. Eur. J, Pharm. Biopharm. 2000; 49: 103-109.
52. Feng SS, Mu L, Win KY, Huang G. Nanoparticle of biodegradable polymers for clinical administration of paclitaxel. Curr. Med. Chem. 2004; 11: 413-424.
53. Fromm MF. P-glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drugs. Int. J. Clin. Pharmacol. Ther. 2000; 38: 69-74.
54. Couvreur P, Kante B, Grislain L, Roland M, Speiser P. Toxicity of polyalkylcyanoacrylate nanoparticles II: Doxorubicin-loaded nanoparticles. J. Pharm. Sci. 1982; 71: 790-792.
55. Gelperina SE, Khalansky AS, Skidan IN, Smirnova ZS, Bobruskin AI, Severin SE, Turowski B, Zanella FE, Kreuter J. Toxicological studies of doxorubicin bound to polysorbate 80-coated polybutyl cyanoacrylate) nanoparticles in healthy rats and rats with intracranial glioblastoma. Toxicol. Lett. 2002; 126: 131-141.
56. Santra S, Zhang P, Wang K, Tapec R, Tan W. Conjugation of biomolecules with luminophore-doped silica nanoparticles for photostable biomarkers. Anal. Chem. 2001; 73: 4988-4993.
57. Lucke A, Fustella E, Tessmar J, Gazzaniga A, Gopferich A. The effect of poly(ethylene glycol)-poly(D,L-lactic acid) diblock copolymers on peptide acylation. J. Control. Rel. 2002; 80: 157-168.
58. Schwendeman SP. Recent advances in the stabilization of proteins encapsulated in injectable PLGA delivery systems. Crit. Rev. Ther. Drug Carrier Syst. 2002; 19: 73-98.
59. Van de Weert M, Hennink WE, Jiskoot W. Protein instability in poly (lactic-co-glycolic acid) microparticles. Pharm. Res. 2000; 17: 1159-1167.
60. Zambaux MF, Bonneaux F, Gref R, Dellacherie E, Vigneron C. Preparation and characterization of protein C-loaded PLA nanoparticles. J. Control Rel. 1999; 60: 179-188.
61. Tobio M, Gref R, Sanchez A, Langer R, Alonso MJ. Stealth PLA-PEG nanoparticles as protein carriers for nasal administration. Pharm. Res. 1998; 15: 270-275.
62. Gaspar MM, Blanco D, Cruz MEM, Alonso MJ. Formulation of asparaginase-loaded poly (lactide-co-glycolide) nanoparticles: influence of polymer properties on enzyme loading, activity and in vitro release. J. Control Rel. 1998; 52: 53-62.
63. Blanco MD, Alonso MJ. Development and characterization of protein-loaded poly(lactide-co-glycolide) nanospheres. Eur. J. Pharm. Biopharm. 1997; 43: 287-294.
64. Pean JM, Boury F, Venier-Julienne MC, Menei P, Proust JE, Benoit JP. Why does PEG 400 coencapsulation improve NGF stability and release from PLGA biodegradable microspheres? Pharm. Res. 1999; 16: 1294-1299.
65. Sanchez A, Tobio M, Gonzalez L, Fabra A, Alonso MJ. Biodegradable micro- and nanoparticles as long-term delivery vehicles for interferon-α. Eur. J. Pharm. Sci. 2003; 18: 221-229.
66. Cleland JL. Protein delivery from biodegradable microspheres. Pharm. Biotechnol. 1997; 10: 1-43.
67. Schroeder U, Sommerfeld P, Ulrich S, Sabel BA. Nanoparticle technology for delivery of drugs across the blood-brain barrier. J. Pharm. Sci. 1998; 87: 1305-1307.
68. Alyautdin RN, Tezikov EB, Ramge P, Khakevich DA, Begley DJ, Kreuter J. Significant entry of tubocurarine into the brain of rats by absorption to polysorbate 80-coated polybutyl-cyanoacrylate nanoparticles: an in situ brain perfusion study. J. Microencapsul. 1998; 15: 67-74.
69. Aktas Y, Yemisci M, Andrieux K, Gürsoy RN, Alonso MJ, Fernandez-Megia E, Novoa-Carballal R, Quiñoá E, Riguera R, Sargon MF, Çelik HH, Demir AS, Hincal AA, Dalkara T, Çapan Y. Couvreur. Development and brain delivery of chitosan-PEG nanoparticles functionalized with the monoclonal antibody OX26. Bioconjug. Chem. 2005; 16: 1503-1511.
70. Xie YL, Lu W, Jiang XG. Improvement of cationic albumin conjugated pegylated nanoparticles holding NC-1900, a vasopressin fragment analog, in memory deficits induced by scopolamine in mice. Behav. Brain Res. 2006; 173: 76-84.
71. Qian ZM, Li H, Sun H, Ho K. Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway. Pharmacol. Rev. 2002; 4: 561-587.
72. Marty JJ, Oppenheim RC, Speiser P. Nanoparticles-a new colloidal drug delivery system. Pharm. Acta Helv. 1978; 53: 17-23.
73. Widder KJ, Senyei AE, Ranney DF. Magnetically responsive microspheres and other carriers for the biological targeting of antitumor agents. Adv. Pharmacol. Chemother. 1979; 16: 213-271.
74. Couvreur P, Kante B, Roland M, Guiot P, Baudhin P, Speiser P. Polycyanoacrylate nanocapsules as potential lysosomotropic carriers: preparation, morphological and sorptive properties. J. Pharm. Pharmacol. 1979; 31: 331-332.
75. Gurny R, Peppas NA, Harrington DD, Banker GS. Development of biodegradable and injectable lattices for controlled release of potent drugs. Drug Dev. Ind. Pharm. 1981; 7: 1-25.
76. Vinogradov SV, Batrakova EV, Kabanov AV. Poly (ethylene glycol)-polyethyleneimine nanogel particles: novel drug delivery systems for antisense oligonucleotides. Colloids Surf. B: Biointerfaces 1999; 16: 291-304.
77. Vinogradov SV, Batrakova EV, Kabanov AV. Nanogels for oligonucleotide delivery to the brain, Bioconjug. Chem. 2004; 15: 50-60.
78. Giralt E, Cid P, Pastor JJ, Gulin OP, Rabanal F. Synthesized polypeptides as drug delivery matrix. U.S. Pat. Appl. Publ. 2005; US 2005276783 Al.
79. Grislain L, Couvreur P, Lenaerts V, Roland M, Deprez-Decampeneere D, Speiser P. Pharmacokinetics and distribution of a biodegradable drug-carrier. Int. J. Pharm. 1983; 15: 335-345.
80. Berscht PC, Nies B, Liebendorfer A, Kreuter J. Incorporation of basic fibroblast growth factor into methylpyrrolidinone chitosan fleeces and determination of the in vitro release characteristics. Biomaterials 1994; 15: 593-600.
81. Milas L, Mason KA, Hunter N, Li C, Wallace S. Poly(L-glutamic acid)-paclitaxel conjugated is a potent enhancer of tumor radiocurability. Int. J. Radiat. Oncol. Biol. Phys. 2003; 55: 707-712.
82. Li C, Newman RA, Wu QP, Ke S, Chen W, Hutto T, Kan Z, Brannan MD, Charnsangavej C, Wallace S. Biodistribution of paclitaxel and poly (L-glutamic acid)-paclitaxel conjugate in mice with OCa-1 tumor. Cancer Chemother. Pharmacol. 2000; 46: 416-422.
83. Kratzer I, Wernig K, Panzenboeck U, Bernhart E, Reicher H, Wronski R, Windisch M, Hammerr A, Malle E, Zimmer A, Sattler W. Apolipoprotein A-I coating of protamine-oligonucleotide nanoparticles increases particle uptake and transcytosis in an in vitro model of the blood-brain barrier. J. Control. Rel. 2007; 117: 301-311.
84. Lu W, Sun Q, Wan J, She Z, Jiang XG. Cationic albumin-conjugated pegylated nanoparticles allow gene delivery into brain tumors via intravenous administration. Cancer Res. 2006; 66: 11878-11887.
85. Kreuter J. Influence of the surface properties on nanoparticle mediated transport of drugs to the brain. J. Nanosci. Nanotechnol. 2004; 4: 484-488.
86. Kreuter J, Ramge P, Petrov V, hamm S, Gelperina SE, Engelhardt B, Alyautdin R, Von Briesen H, Begley DJ. Direct evidence that polysorbate-80-coated poly(butylcyanoacrylate) nanoparticles deliver drugs to the CNS via specific mechanisms requiring prior binding of drug to the nanoparticles. Pharm. Res. 2003; 20: 409-416.
87. Alyaudtin RN, Reichel A, Lobenberg R, Ramge P, Kreuter J, Begley DJ. Interaction of poly(butylcyanoacrylate) nanoparticles with the blood-brain barrier in vivo and in vitro. J. Drug Target. 2001; 9: 209-221.
88. Calvo P, Gouritin B, Chacun H, Desmaële D, D'Angelo J, Noel JP, Georgin D, Fattal E, Andreux JP, Couvreur P. Long-circulating PEGylated polycyanoacrylate nanoparticles as new drug carrier for brain delivery. Pharm. Res. 2001; 18: 1157-1165.
89. Bazile D, Prud'homme C, Bassoullet MT, Marland M, Spenlehauer G, Veillard M. Stealth Me.PEG-PLA Nanoparticles Avoid Uptake by the mononuclear phagocytes system. J. Pharm. Sci. 1995; 84: 493-498.
90. Zambaux MF, Faivre-Fiorina B, Bonneaux F, Marchal S, Merlin JL, Dellacherie E, Labrude P, Vigneron C. Involvement of neutrophilic granulocytes in the uptake of biodegradable non-stealth and stealth nanoparticles in guinea pig. Biomaterials 2000; 21: 975-980.
91. Gulyaev AE, Gelperina SE, Skidan IN, Antropov AS, Kivman GY, Kreuter J. Significant transport of doxorubicin into the brain with polysorbate 80-coated nanoparticles. Pharm. Res. 1999; 16: 1564-1569.
92. 3H-labelled dalargin bound to poly (butyl cyanoacrylate) nanoparticle after I.V. injections to mice. Life Sci. 2000; 66: 495-502.
93. Das D, Lin S. Double-coated poly (butylcyanoacrylate) nanoparticulate delivery systems for brain targeting of dalargin via oral administration. J. Pharm. Sci. 2005; 94: 1343-1353.
94. Tobío M, Sánchez A, Vial A, Soriano I, Evora C, Vila-Jato JL, Alonso MJ. The role of PEG on the stability in digestive fluids and in vivo fate of PEG-PLA nanoparticle following oral administration. Coll. Surf. B: Biointerf. 2000; 18: 315-323.
95. Landry FB, Bazile DV, Spenlehauer G, Veillard M, Kreuter J. Influence of coating agents on the degradation of poly (lactic acid) nanoparticles in model digestive fluids (USP XXII). STP Pharm. Sci. 1996; 63: 195-202.
96. Moghini S, Muir I, illum L, Davis S, KohlBachofen V. Coating particles with a block copolymer (poloxamine 908) suppresses opsonization but permits the activity of dysopsonin in the serum. Biochem. Biophys. Acta 1993; 1179: 157-165.
97. Klibanov AL, Maruyama K, Torchilin VP, Huang L. Amphiphatic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett. 1990; 268: 235-237.
98. Torchilin VP, Papisov MI. Hipótesis: Why do polyethylene glycol-coated liposomes circulate so long? J. Liposome Res. 1994; 4: 725-739.
99. Olivier JC, Huerta R, Lee HJ, Calon F, Pardridge WM. Synthesis of pegylated immunonanoparticles. Pharm Res. 2002; 19: 1137-1143.
100. Lee JH, Engler JA, Collawn JF, Moore BA. Receptor mediated uptake of peptides that bind the human transferrin receptor. Eur. J. Biochem. 2001; 268: 2004-2012.
101. Pujals S, Sabido E, Tarrago T, Giralt E. All-D proline-rich cell-penetrating peptides: a preliminary in vivo internalization study. Biochem. Soc. Trans. 2007; 35: 794-796.
102. Santra S, Yang H, Dutta D, Stanley JT, Holloway PH, Tan W, Moudgil BM, Mericle RA. TAT conjugated, FITC doped silica nanoparticles for bioimaging applications. Chem. Commun. 2004; 24: 2810-2811.
103. Xiang JJ, Zhu SG, Li GY. Using iron oxide nanoparticles as gene carrier. Chin. J. Cancer 2001; 20: 1-6.
104. Xiang JJ, Tang JQ, Zhu SG, Nie XM, Lu HB, Shen SR, Li XL, Tang K, Zhou M, Li GY. IONP-PLL: a novel non-viral vector for efficient gene delivery. J. Gene Med. 2003; 5: 803-817.
105. Constantino L, Gandolfi F, Tosi G, Rivasi F, Vandelli MA, Forni F. Peptide-derivatized biodegradable nanoparticles able to cross the blood brain barrier. J. Control. Rel. 2005; 108: 84-96.
106. Constantino L, Gandolfi F, Bossy-Nobs L, Tosi G, Gurny R, Rivasi F, Vandelli MA, Forni F. Nanoparticulate drug carriers based on hybrid poly(D,L-lactide-co-glycolide)-dendron structures, Biomaterials 2006; 27: 4635-4645.
107. Crespo L, Sanclimens G, Montaner B, Pérez-Tomás R, Royo M, Pons M, Albericio F, Giralt E. Peptide dendrimers based on polyproline helices. J. Am. Chem. Soc. 2002; 124: 8876-8883.
108. Sanclimens G, Shen H, Giralt E, Albericio F, Saltzman MW, Royo M. Synthesis and screening of a small library of proline-based biodendrimers for use as delivery agents. Biopolymers 2005; 80: 800-814.
109. Gessner A, Olbrich C, Schröder W, kayser O, Müller RH. The role of plasma proteins in brain targeting: species dependent protein adsorption patterns on brain-specific lipid drug conjugate (LDC) nanoparticles. Int. J. Pharm. 2001; 214: 87-91.
110. Olivier JC, Fenart L, Chauvet R, Pariat C, Cecchelli R, Couet W. Indirect evidence that drug brain targeting using polysorbate 80-coated polybutylcyanoacrylate nanoparticles is related o toxicity. Pharm. Res. 1999; 16: 1836-1842.
111. Lockman PR, Koziara J, Roder KE, Paulson J, Abbruscato TJ, Mumper RJ, Allen DD. In vivo and in vitro assessment of baseline blood-brain barrier parameters in the presence of novel nanoparticles. Pharm. Res. 2003; 20: 705-713.
112. Petri B, Bootz A, Khalansky A, Hekmatara T, Müller R, Uhl R, Kreuter J, Gelperina S. Chemotherapy of brain tumor using doxorubicin bound to surfactant-coated poly(butyl cyanoacrylate) nanoparticles: revisiting the role of surfactants. J. Control. Rel. 2007; 117: 51-58.
113. Amer DAM, Irvine GB, El-Agnaf OMA. Inhibitors of α -synuclein oligomerization and toxicity: a future therapeutic strategy for Parkinson's disease and related disorders. Exp. Brain Res. 2006; 173: 223-233.
114. Kokkoni N, Stott K, Amijee H, Mason JM, Doig AJ. N-methylated peptide inhibitors of β-amyloid aggregation and toxicity. Optimization of the inhibitor structure. Biochemistry. 2006; 45: 9906-9918.
115. Lu W, Zhang Y, Tan YZ, Hu KL, Jiang XG, Fu SK. Cationic albumin-conjugated pegylated nanoparticles as novel drug carrier for brain delivery. J. Control. Rel. 2005; 107: 428-448.
116. Lu W, Wan J, Zhang Q, She Z, Jiang X. Aclarubicin-loaded cationic albumin-conjugated pegylated nanoparticle for glioma chemotherapy in rats. Int. J. Cancer 2006; 120: 420-431.
117. Lu W, Tan YZ, Hu KL, Jiang Xg. Cationic albumin conjugated pegylated nanoparticles with its transcytosis ability and little toxicity against blood-brain barrier. Int. J. Pharm. 2005; 295: 247-260.
118. Sun W, Wang H, Xie C, Hu Y, Yang X, Xs H. An attempt to directly trace polymeric nanoparticles in vivo with electrón microscopy. J. Control. Rel. 2006; 115: 259-265.
119. Koziara JM, Lockman PR, Allen DD, Mumper RJ. Paclitaxel nanoparticles for the potential treatment of brain tumors. J. Control. Rel. 2004; 99: 259-269.
120. Lockman PR, Oyewumi MO, Koziara JM, Roder KE, Mumper RJ, Allen DD. Brain uptake of thiamine-coated nanoparticles. J. Control. Rel. 2003; 93: 271-282.
121. Koziara JM, Lockman PR, Allen DD, Mumper RJ. In situ blood-brain barrier transport of nanoparticles. Pharm. Res. 2003; 20: 1772-1778.
122. Alyautdin RN, Petrov VE, Langer K, berthold A, Kharkevich DA, Kreuter J. Delivery of loperamide across the blood-brain barrier with polysorbate 80-coated polybutylcyanoacrylate nanoparticles. Pharm. Res. 1997; 14: 325-328.
123. Gao K, Jiang X. Influence of particle size on transport of methotrexate across the blood-brain barrier by polysorbate 80-coated polybutylcyanoacrylate nanoparticles. Int. J. Pharm. 2006; 310: 213-219.
124. Ramge P, Unger RE, Oltrogge JB, Zenker D, begley D, Kreuter J, Von Briesen H. Polysorbate-80 coating enhances uptake of polybutylcyanoacrylate (PBCA)-nanoparticles by human and bovine primary brain capillary endothelial cells. Eur. J. Neurosci. 2000; 12: 1931-1940.
125. Garcia-Garcia E, Gil S, Andrieux K, Desmaële D, Nicolas V, Taran F, Georgin D, Andreux JP, Roux F, Couvreur P. A relevant in vitro rat model for the evaluation of the blood-brain barrier translocation of nanoparticles. Cell. Mol. Life Sci. 2005; 62: 1400-1408.
126. Kuo YC, Chen HH. Effect of nanoparticulate polybutylcyanoacrylate and methylmethacrylate-sulfopropylmethacrylate on the permeability of zidovudine and lamivudine across the in vivo blood-brain barrier. Int. J. Pharm. 2006; 327: 160-169.